论文部分内容阅读
为贯彻《中华人民共和国中医药法》(中华人民共和国主席令第59号)、《国务院关于改革药品医疗器械审评审批制度的意见》(国发[2015]44号)、《国家食品药品监管总局关于药品注册审评审批若干政策的公告》(2015年第230号)精神,加快中药复方新药药理研究与临床转化、推动构建适合中药特点的新药审评创新体系,加强对近几年来中药有效性评价体系中“证候评价”研究新进展的交流,促进我国中药有效性及安全性
In order to implement the “Chinese Medicine Law of the People’s Republic of China” (Chairman’s Decree No.59 of the People’s Republic of China), the “Opinions of the State Council on Reforming the Examination and Approval System of Medical Devices for Medical Products” (Guo Fa [2015] No. 44), the State Food and Drug Administration Administration of Quality Supervision, Inspection and Quarantine of the People’s Republic of China “(No. 230 of 2015) to speed up the pharmacological research and clinical transformation of new drugs of traditional Chinese medicine and promote the establishment of a new drug evaluation and innovation system suitable for the characteristics of traditional Chinese medicines, and to strengthen the effectiveness of traditional Chinese medicine in recent years Sexual Evaluation System, ”Symposium Evaluation " new developments in the exchange of research to promote the effectiveness of Chinese medicine and safety